Rallybio Stock Faces a $50 Million Test as Traders Weigh What Comes Next
Rallybio shares last traded at $14.52, holding steady after receiving a $50 million break fee from Candid Therapeutics’ canceled merger. The payment now accounts for about two-thirds of Rallybio’s equity value. No new company news has moved the stock, and its lead drug candidate remains far from approval. Trading volume Thursday was 21,282 shares.